Interim data from a phase 3 study evaluating tecovirimat for the treatment of human mpox virus showed the antiviral did not improve time to lesion resolution compared with placebo.

Screening recommended every three years with cervical cytology for women aged 21 to 29 years, every five years with hrHPV screening at age 30 to 65 years ...

(HealthDay News) — Vitamin D 3 supplementation does not significantly reduce the risk for developing diabetes among older adults who are not at high risk for diabetes, according to a study published ...

The newly approved regimen is expected to simplify administration and potentially reduce medication errors and dose-related reactions.

The Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for paltusotine for the treatment and long-term maintenance of acromegaly in adults.

At all time points, consistently high levels of patient satisfaction were observed (>84% reporting much or very much improved).

The FDA is expected to decide on treatments for EBV-positive posttransplant lymphoproliferative disease, breast cancer, Barth syndrome, pain, and migraine.

The single-arm, open-label APPULSE-PNH trial included 52 PNH patients who were on a stable regimen with either eculizumab or ravulizumab.

(HealthDay News) — Increased consumption of dark chocolate, but not milk chocolate, is associated with a reduced risk for type 2 diabetes (T2D), according to a study published online Dec. 4 in The BMJ ...

Patients should be selected for treatment based on the presence of an NRG1 gene fusion in tumor specimens.

The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), as a single agent, for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has ...

B, Recombivax HB, or Twinrix as hepatitis B vaccination recommendations that providers can give pregnant patients.